Extended treatment with single-agent ibrutinib at the 420 mg dose leads to durable responses in chronic lymphocytic leukemia/small lymphocytic lymphoma

PURPOSE: Ibrutinib, a first-in-class, once-daily, oral inhibitor of Bruton’s tyrosine kinase, promotes apoptosis, and inhibits B-cell proliferation, adhesion, and migration. Ibrutinib has demonstrated single-agent efficacy and acceptable tolerability at doses of 420 and 840 mg in patients with chron...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Clin Cancer Res
Main Authors: Coutré, Steven E., Furman, Richard R, Flinn, Ian W., Burger, Jan A., Blum, Kristie, Sharman, Jeff, Jones, Jeffrey, Wierda, William, Zhao, Weiqiang, Heerema, Nyla A., Johnson, Amy J., Tran, Anh, Zhou, Cathy, Bilotti, Elizabeth, James, Danelle F., Byrd, John C., O’Brien, Susan
Format: Artigo
Sprog:Inglês
Udgivet: 2017
Fag:
Article
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6317338/
https://ncbi.nlm.nih.gov/pubmed/28073846
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-16-1431
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker